R R

What Is Qulipta?

Qulipta is a prescription medication containing atogepant, a calcitonin gene-related peptide (CGRP) receptor antagonist. It is approved for the preventive treatment of migraine in adults, including episodic and chronic migraine. Qulipta is available as oral tablets taken once daily. It works by blocking a signaling pathway involved in migraine attacks rather than acting as a traditional pain reliever. Qulipta is not intended to stop a migraine attack that has already started. Treatment selection depends on migraine frequency, kidney and liver function, medication interactions, and the patient's response to previous preventive therapies.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Qulipta?

Qulipta is a prescription medication containing atogepant, a calcitonin gene-related peptide (CGRP) receptor antagonist. It is approved for the preventive treatment of migraine in adults, including episodic and chronic migraine. Qulipta is available as oral tablets taken once daily. It works by blocking a signaling pathway involved in migraine attacks rather than acting as a traditional pain reliever. Qulipta is not intended to stop a migraine attack that has already started. Treatment selection depends on migraine frequency, kidney and liver function, medication interactions, and the patient's response to previous preventive therapies.

read more about qulipta ...

Copy this HTML:

Copy HTML Copied!

How Does Qulipta Work?

Qulipta blocks receptors for calcitonin gene-related peptide, a signaling molecule involved in migraine-related pain pathways. CGRP contributes to nerve signaling and blood vessel responses associated with migraine attacks. By preventing CGRP from activating its receptors, atogepant helps reduce the frequency of migraine episodes over time. Qulipta does not constrict blood vessels through the mechanism used by triptan medications. Its preventive benefit develops with regular dosing, and patients may still experience occasional migraines during treatment. Acute migraine medications may remain necessary for attacks that occur despite preventive therapy.

What Types of Migraine Does Qulipta Prevent?

Qulipta is approved to prevent both episodic and chronic migraine in adults. Episodic migraine generally involves fewer than 15 headache days per month, while chronic migraine involves at least 15 headache days monthly, including at least eight days with migraine features, for more than three months. A healthcare professional reviews headache frequency, severity, disability, other conditions, and previous medications before prescribing Qulipta. It does not treat cluster headaches or every type of chronic headache. Qulipta is not approved for pediatric use or for immediate relief during an active migraine attack.

How Should Qulipta Be Taken?

Qulipta is taken orally once daily, with or without food. For episodic migraine prevention, recommended doses are 10 mg, 30 mg, or 60 mg daily. For chronic migraine prevention, the recommended dose is 60 mg daily. Patients with severe kidney impairment or end-stage renal disease may receive 10 mg daily for episodic migraine, while Qulipta is not recommended for chronic migraine in those patients. Dose adjustments or avoidance may also be necessary with certain CYP3A4 inhibitors, inducers, or OATP inhibitors. Patients should take Qulipta consistently and follow their clinician's instructions for any missed dose.

What Are the Side Effects and Warnings of Qulipta?

Common adverse effects include nausea, constipation, fatigue, and sleepiness. Serious hypersensitivity reactions, including anaphylaxis, difficulty breathing, and facial swelling, have been reported and may occur days after administration. New or worsening hypertension and Raynaud's phenomenon have also been reported with CGRP receptor antagonists, including Qulipta. Patients should monitor blood pressure when directed and report unusual coldness, pain, or color changes in the fingers or toes. Qulipta is not recommended for patients with severe liver impairment. Significant allergic symptoms require immediate medical attention.

Common Questions About Qulipta

Is Qulipta the same as atogepant?

Yes. Qulipta is the brand name for atogepant, an oral CGRP receptor antagonist used for migraine prevention in adults.

Can Qulipta stop an active migraine?

No. Qulipta is approved for preventive treatment. Patients may need a separate medication for migraine attacks that occur during treatment.

Is Qulipta taken every day?

Yes. Qulipta is taken once daily, with the prescribed dose depending on the migraine type and patient-specific factors.

Can Qulipta cause constipation?

Yes. Constipation is one of the most commonly reported adverse effects of Qulipta, along with nausea and fatigue or sleepiness.

References

Atogepant. MedlinePlus. https://medlineplus.gov/druginfo/meds/a621052.html. Date Accessed November 3, 2026.

Atogepant. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Atogepant. Date Accessed November 3, 2026.

DailyMed - QULIPTA (atogepant) tablet. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c8ab8f4-32bd-497a-befa-70c8a51d8d52. Date Accessed November 3, 2026.

Qulipta. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/aquipta. Date Accessed November 3, 2026.

QULIPTA Prescribing Information. AbbVie. https://www.rxabbvie.com/pdf/qulipta_pi.pdf. Date Accessed November 3, 2026.